ArticleAntimicrobial agents and chemotherapy2015
Stearylamine Liposomal Delivery of Monensin in Combination with Free Artemisinin Eliminates Blood Stages of Plasmodium falciparum in Culture and P. berghei Infection in Murine Malaria.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 64 citations in OpenAlex.
- Development of Nanotechnological Approaches to Improving the Antimalarial Potential of Natural Substances.Molecules (Basel, Switzerland) · 2025Review
- Current Trends in Nanotechnology-Based Drug Delivery Systems for the Diagnosis and Treatment of Malaria: A Review.Current drug delivery · 2025Review
- Research Progress on Strategies for Improving the Enzyme Properties of Bacteriophage Endolysins.Journal of microbiology and biotechnology · 2024Review
- Plant-based nanoparticles targeting malaria management.Frontiers in pharmacology · 2024Review
- Repurposing Polyether Ionophores as a New-Class of Anti-SARS-Cov-2 Agents as Adjunct Therapy.Current microbiology · 2023Review
- Single-Chain Polymer Nanoparticles Targeting the Ookinete Stage of Malaria Parasites.ACS infectious diseases · 2023Article
- Preliminary Assessment of Intramuscular Depot of Lipid-Based Decoquinate Formulation for Long-Term Chemoprophylaxis of Malaria.Pharmaceutics · 2022Article
- Quality by Design-Driven Zeta Potential Optimisation Study of Liposomes with Charge Imparting Membrane Additives.Pharmaceutics · 2022Article
- Current challenges and nanotechnology-based pharmaceutical strategies for the treatment and control of malaria.Parasite epidemiology and control · 2022Review
- Liposomes as Multifunctional Nano-Carriers for Medicinal Natural Products.Frontiers in chemistry · 2022Review
- Review of the Current Landscape of the Potential of Nanotechnology for Future Malaria Diagnosis, Treatment, and Vaccination Strategies.Pharmaceutics · 2021Review
- Liposomes for malaria management: the evolution from 1980 to 2020.Malaria journal · 2021Review
- Azacarbazole n-3 and n-6 polyunsaturated fatty acids ethyl esters nanoemulsion with enhanced efficacy againstBioactive materials · 2021Article
- A Novel, Nontoxic and Scalable Process to Produce Lipidic Vehicles.Materials (Basel, Switzerland) · 2020Article
- Continuous-Flow Production of Liposomes with a Millireactor under Varying Fluidic Conditions.Pharmaceutics · 2020Article
- Nanobiotechnological modules as molecular target tracker for the treatment and prevention of malaria: options and opportunity.Drug delivery and translational research · 2020Review
- Preclinical Evidence of Nanomedicine Formulation to TargetPathogens (Basel, Switzerland) · 2020Article
- A symbiotic bacterium of shipworms produces a compound with broad spectrum anti-apicomplexan activity.PLoS pathogens · 2020Article
- Nanoparticles for antiparasitic drug delivery.Drug delivery · 2019Review
- Combination Therapy Strategies for the Treatment of Malaria.Molecules (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global emergence of drug resistance in malaria is impeding the therapeutic efficacy of existing antimalarial drugs. Therefore, there is a critical need to develop an efficient drug delivery system to circumvent drug resistance. The anticoccidial drug monensin, a carboxylic ionophore, has been shown to have antimalarial properties. Here, we developed a liposome-based drug delivery of monensin and evaluated its antimalarial activity in lipid formulations of soya phosphatidylcholine (SPC) cholesterol (Chol) containing either stearylamine (SA) or phosphatidic acid (PA) and different densities of distearoyl phosphatidylethanolamine-methoxy-polyethylene glycol 2000 (DSPE-mPEG-2000). These formulations were found to be more effective than a comparable dose of free monensin in Plasmodium falciparum (3D7) cultures and established mice models of Plasmodium berghei strains NK65 and ANKA. Parasite killing was determined by a radiolabeled [(3)H]hypoxanthine incorporation assay (in vitro) and microscopic counting of Giemsa-stained infected erythrocytes (in vivo). The enhancement of antimalarial activity was dependent on the liposomal lipid composition and preferential uptake by infected red blood cells (RBCs). The antiplasmodial activity of monensin in SA liposome (50% inhibitory concentration [IC50], 0.74 nM) and SPC:Chol-liposome with 5 mol% DSPE-mPEG 2000 (IC50, 0.39 nM) was superior to that of free monensin (IC50, 3.17 nM), without causing hemolysis of erythrocytes. Liposomes exhibited a spherical shape, with sizes ranging from 90 to 120 nm, as measured by dynamic light scattering and high-resolution electron microscopy. Monensin in long-circulating liposomes of stearylamine with 5 mol% DSPE-mPEG 2000 in combination with free artemisinin resulted in enhanced killing of parasites, prevented parasite recrudescence, and improved survival. This is the first report to demonstrate that monensin in PEGylated stearylamine (SA) liposome has therapeutic potential against malaria infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.